OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 4th
November 24 2008 - 11:00AM
Business Wire
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that it
will host a live webcast of its R&D Analyst Day on Thursday,
December 4, 2008 at 12:30 p.m. Eastern Time. The webcast will be
hosted by Colin Goddard, Ph.D., Chief Executive Officer, and
members of OSI�s management team. The Company will discuss the
status of its oncology and diabetes/obesity research and
development programs, including its Tarceva� (erlotinib) program.
The webcast is expected to last approximately three hours. To
access the webcast live via the Internet, please log onto
www.osip.com approximately 15 minutes before the start of the event
to allow for any software downloads that may be necessary.
Following the webcast, an archive will be available at the same
address until approximately December 31, 2008. About OSI
Pharmaceuticals OSI Pharmaceuticals is committed to "shaping
medicine and changing lives" by discovering, developing and
commercializing high-quality and novel pharmaceutical products
designed to extend life and/or improve the quality of life for
patients with cancer and diabetes/obesity. The Company�s oncology
programs are focused on developing molecular targeted therapies
designed to change the paradigm of cancer care. OSI�s
diabetes/obesity efforts are committed to the generation of novel,
targeted therapies for the treatment of type 2 diabetes and
obesity. OSI's flagship product, Tarceva� (erlotinib), is the first
drug discovered and developed by OSI to obtain FDA approval and the
only EGFR inhibitor to have demonstrated the ability to improve
survival in both non-small cell lung cancer and pancreatic cancer
patients in certain settings. OSI markets Tarceva through
partnerships with Genentech, Inc. in the United States and with
Roche throughout the rest of the world. For additional information
about OSI, please visit . This news release contains
forward-looking statements. These statements are subject to known
and unknown risks and uncertainties that may cause actual future
experience and results to differ materially from the statements
made. Factors that might cause such a difference include, among
others, the completion of clinical trials, the FDA review process
and other governmental regulation, OSI's and its collaborators'
abilities to successfully develop and commercialize drug
candidates, competition from other pharmaceutical companies, the
ability to effectively market products, and other factors described
in OSI Pharmaceuticals' filings with the Securities and Exchange
Commission.
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024